Now is a Good Time to Buy Novartis, Here's Why

NYSE: NVS | Novartis AG ADR News, Ratings, and Charts

NVS – Novartis AG (NVS) is expected to soar in the upcoming months based on its impressive financial performance, continued efforts to add new products to its portfolio, and the underlying strength of the pharma industry.

Novartis AG (NVS) researches, develops, and markets healthcare products worldwide. It primarily operates through two segments – Innovative Medicines and Sandoz. As a leading provider of healthcare products globally, the company deploys innovative science and digital technologies to create transformative treatments. Novartis products reach nearly 800 million people globally.

NVS has recently reported that the European Medicines Agency (EMA) has approved the safety label update for Novartis Beovu, a clinically advanced humanized single-chain antibody fragment, after a positive top-line results from the first Phase III trial of Beovu versus aflibercept in patients with diabetic macular edema (DME). NVS also collaborated with the Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines.

In the second quarter, the company’s core operating income increased 6% in constant currency and its earnings per share was up 6% year-over-year. In July, NVS launched a first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19. This impressive performance and the potential upside based on a number of factors has helped it earn a “Buy” rating in our proprietary rating system.

Here is how our proprietary POWR Ratings system evaluates NVS:

Trade Grade: A

NVS is presently trading higher than its 50-day and 200-day moving averages of $86.21 and $87.96, respectively, indicating that the stock is in an uptrend. In fact, the stock’s 4.9% return over the past month reflects short-term bullishness.

The company witnessed a series of new approvals from both the FDA and international agencies during the last quarter. Innovative Medicines net sales were USD 9.2 billion for the last reported quarter, up 1% year-over-year in constant currency. Net sales of the top 20 Innovative Medicines products of the company during the quarter increased 2% in constant currency to $7.1 billion.

Buy & Hold Grade: B

NVS is well positioned in terms of proximity to its 52-week high, which is a key factor that our Buy & Hold Grade takes into account. The stock is currently trading 10% below its 52-week high.

The stock has gained close to 30% in the last three years due to its aggressive research and development, successful clinical trials of its diversified product-line and improving margins. It has an impressive history of earnings growth. The company’s EBIT grew at a CAGR of 15.4% over the past three years. 

As part of the second-quarter results, NVS mentioned, “We are on track to deliver on our commitment to drive consistent margin expansion and are excited by the progress of our deep mid to late stage pipeline to drive long-term growth.”

Peer Grade: A

NVS is currently ranked #19 out of 232 stocks in the Medical – Pharmaceuticals industry. Other popular stocks in the industry are Johnson & Johnson (JNJ), Merck & Company, Inc. (MRK) and Novo Nordisk A/S (NVO). NVS has lost 2.9% year-to-date. While JNJ and NVO beat NVS by gaining 3.8% and 19.2%, respectively, over this period, MRK has lost 3.7%. However, in terms of product pipeline and financials, NVS is better positioned than many of its peers.

Industry Rank: B

The Medical – Pharmaceuticals industry is ranked #5 out of the 123 StockNews.com industries. Since the onset of the health crisis, the pharma industry has initiated the development of dozens of potential vaccines for the COVID-19 pandemic in record time. The industry has made huge achievements over time to research into new antibiotics. Moreover, data science and AI have the potential to transform drug discovery in terms of costs, speed and efficiency.

Overall POWR Rating: B (Buy)

Overall, NVS is rated a “Buy” due to its impressive past performance, short-and-long-term developments, and recent price momentum, as determined by the four components of our overall POWR Rating.

Bottom Line

Despite losing 3.9% so far this year, NVS has the potential to grow based on its continued business growth and favorable research and development expenditures. The company is trying to mitigate the negative impact of exchange rates on its operations. NVS is optimistic to return to its leadership position in the global healthcare systems, primarily in the prescription dynamics.

Analyst sentiment, which gives a good sense of a stock’s future price movement, is pretty impressive for NVS.  Of the 22 Wall Street analysts that rated the stock, 12 have given it a “Strong Buy” rating. The market expects EPS to rise 9.3% next year.

Want More Great Investing Ideas?

7 Best ETFs for the NEXT Bull Market

Stock Market Outlook: Before & After the Election

Chart of the Day- See the Stocks Ready to Breakout


NVS shares were unchanged in after-hours trading Thursday. Year-to-date, NVS has declined -1.66%, versus a 5.42% rise in the benchmark S&P 500 index during the same period.


About the Author: Sidharath Gupta


Sidharath’s passion for the markets and his love of words guided him to becoming a financial journalist. He began his career as an Equity Analyst, researching stocks and preparing in-depth research reports. Sidharath is currently pursuing the CFA program to deepen his knowledge of financial anlaysis and investment strategies. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
NVSGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

3 Energy Stocks Set to Soar Beyond Expectations

Given the geopolitical tensions, increasing global oil demand, and supply adjustments, the energy sector is poised for robust growth. Therefore, investors might consider investing in energy stocks TechnipFMC (FTI), Weatherford International (WFRD), and ChampionX (CHX), which are poised to exceed expectations. Keep reading…

Has Carnival (CCL) Stock Turned Into a Buy After Earnings Release?

Carnival Corporation (CCL) reported record revenue in its most recent quarter but still faces a negative bottom line. The collapse of Francis Scott Key Bridge brings more uncertainty to its financials. Given these events, what stance should one take with CCL stock? Read more to find out…

3 China Stocks Positioned for Long-Term Growth

Despite facing challenges, the Chinese economy has demonstrated resilience, as evidenced by recent robust industrial output and retail sales data. Given this outlook, it might be an opportune time to own three top-notch China stocks, JD.com, Inc. (JD), China Automotive Systems (CAAS), and Youdao, Inc. (DAO). Read on…

Investor Alert: “Buy the Rumor, Sell the News!”

Everyone knows that the Fed is going to cut rates at some point this year. That is the worst kept secret on the planet helping to explain how we keep making new highs for the for the S&P 500 (SPY). Unfortunately that creates an interesting predicament for stocks after rates are cut. Plus another hurdle in the 2024 Presidential election. Steve Reitmeister is here to share his insights on the market outlook along with a preview of his top 12 stocks to outperform. Read on for more...

Read More Stories

More Novartis AG ADR (NVS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All NVS News